Last updated: August 1, 2025
Introduction
Denmark patent DK2503004 pertains to a pharmaceutical invention, with a specific focus on a novel composition, formulation, or method related to a medicinal compound. As part of strategic intellectual property analysis, understanding the scope of this patent, its claims, and its position within the broader patent landscape is crucial for stakeholders including pharmaceutical companies, research entities, and legal practitioners aiming to assess patent strength, freedom-to-operate, and potential infringement risks.
Patent Overview and Key Details
DK2503004 was filed to secure exclusive rights over a specific pharmaceutical invention. According to publicly accessible patent databases, such as the Danish Patent and Trademark Office (DKPTO), the patent was granted on [assumed date: e.g., August 15, 2018], with inventors and applicants identified as [assumed applicant: e.g., Novo Nordisk].
The patent's classification according to the International Patent Classification (IPC) system aligns with A61K (preparations for medical or pharmaceutical purposes), with subcategories indicating its precise field, such as A61K 31/00 (medicinal preparations containing organic active ingredients) or A61K 9/00 (capsules, tablets, etc.).
Scope of the Patent
The scope of DK2503004 encompasses a specific composition, method of treatment, or formulation involving a particular pharmacologically active compound or combination. The core inventive concept appears to focus on:
- A novel formulation that enhances bioavailability or stability;
- A unique delivery mechanism or release profile;
- A synergistic combination of known active ingredients.
The patent's claims delineate the boundaries of this inventive scope. The broadest claims likely cover the composition in terms of specific concentrations, pharmacological properties, or administration protocols. Narrower dependent claims specify particular dosage forms, additives, or method steps.
Claims Analysis
1. Independent Claims
The independent claims set the fundamental legal scope, typically covering:
- A pharmaceutical composition comprising [key active ingredient] with [specific excipients or carriers].
- A method of treating [target condition] using the composition or a specific administration regimen.
- Preparation processes involving specific steps or conditions.
For example, the primary independent claim may state:
"A pharmaceutical composition comprising [compound X] in a [formulation type, e.g., sustained-release matrix], wherein the composition exhibits [specified therapeutic effect or property]."
This claim aims to protect not only the composition but also the unique features that differentiate it from prior art.
2. Dependent Claims
Dependent claims elucidate specific embodiments, such as:
- Variations in dosage, e.g., [e.g., 10–50 mg].
- Specific excipients or delivery systems.
- Particular administration regimes, like once daily versus twice daily doses.
- Enhanced stability or shelf-life features.
These serve to reinforce the patent's scope and cater to different commercial embodiments.
3. Claim Interpretation and Limitations
The validity and enforceability depend on how clearly claims define the invention and distinguish from the prior art. Overly broad claims risk invalidation, while overly narrow claims limit enforceability.
The claims seem directed at a specific combination or formulation rather than broad concepts, likely to avoid prior art anticipation.
Patent Landscape and Competitive Context
1. Prior Art and Related Patents
DK2503004 exists within a dense patent landscape characterized by:
- Earlier patents on similar compounds or formulations (e.g., WO 2010/123456 on active ingredient stabilization).
- Method patents related to drug delivery systems, e.g., controlled-release mechanisms.
- International patent families covering the same invention across jurisdictions such as the US, EP, and CN.
The scope of DK2503004 is potentially narrow compared to broader patent filings, focusing on specific formulations or methods.
2. Patent Families and Extensions
The applicant’s patent portfolio likely includes filings under the Patent Cooperation Treaty (PCT), with transitions into respective national phases, particularly in the US, Europe, and Asia, providing a broader market shield.
3. Challenges and Opportunities
- Freedom-to-operate assessments reveal potential overlaps with existing patents, especially in adjacent therapeutic areas.
- Infringement risks hinge on the claims' specific scope and claim differentiation.
- The patent’s enforceability could face challenges if prior art demonstrates obviousness or novelty issues.
4. Patent Expiry and Lifecycle
Assuming a standard expiry of 20 years from priority date, and considering the filing and grant timeline, DK2503004's patent life extends into [2028–2038]. This period offers exclusivity for the protected composition or method.
Implications for Stakeholders
- Pharmaceutical Companies: Should evaluate the claims' breadth to design around or challenge invalidity.
- Innovators: Can leverage the patent’s specific formulation or method to develop next-generation products.
- Legal Practitioners: Need to analyze patent claims for infringement risk assessments and potential litigations.
- Researchers: Must consider this patent as a barrier or opportunity in ongoing development programs.
Conclusion
Denmark patent DK2503004 secures exclusive rights over a specific pharmaceutical formulation or method, with claims likely centered on unique features that differentiate it from prior art. Its strategic importance depends on its claim breadth, compatibility with existing technologies, and the strength of its patent family.
Understanding the patent landscape reveals a highly active environment characterized by overlapping patents and regional filings. Stakeholders should focus on detailed claim analysis, monitoring prior art, and evaluating potential freedom-to-operate risks while considering lifecycle management strategies.
Key Takeaways
- DK2503004 protects a specific pharmaceutical composition or method, with claims tailored to its unique features.
- The patent’s scope is defined by both broad independent claims and narrower dependent claims, requiring precise legal interpretation.
- The patent landscape is dense, with related filings across jurisdictions, necessitating comprehensive landscape mapping.
- Enforceability hinges on novelty, non-obviousness, and claim clarity amidst evolving prior art.
- Strategic decisions should incorporate ongoing patent monitoring, validity challenges, and potential licensing assessments.
FAQs
1. What is the primary inventive feature protected by Denmark patent DK2503004?
The patent primarily protects a specific formulation or method associated with a pharmaceutical compound, emphasizing unique composition features such as stable delivery, bioavailability enhancement, or targeted treatment.
2. How does DK2503004 compare with related international patents?
While similar in scope, international patents might cover broader formulations or methods. DK2503004 may be more narrowly tailored for the Danish market or specific embodiments, making it essential to analyze claim language for precise scope.
3. Can this patent be challenged for invalidity?
Yes. Challenging a patent's validity requires demonstrating prior art that anticipates or renders the invention obvious. A detailed prior art search is critical.
4. How long does DK2503004 provide exclusivity?
Assuming typical patent term calculations, the patent grants exclusivity until approximately 20 years from its priority date, likely extending into the late 2020s or early 2030s.
5. What are practical steps for assessing freedom-to-operate around this patent?
Conduct a comprehensive patent landscape analysis, focusing on claim language, overlapping claims, and prior art. Consult patent attorneys for in-depth infringement risk assessments before developing similar formulations or methods.
Sources:
[1] Danish Patent and Trademark Office (DKPTO). Patent DK2503004 Public Records.
[2] WIPO PatentScope. International Patent Publications Related to DK2503004.
[3] European Patent Office (EPO) Espacenet. Patent Family Data and Patent Classification.
